AlloVir (ALVR)
(Delayed Data from NSDQ)
$0.80 USD
0.00 (-0.36%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.80 0.00 (0.36%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
AlloVir, Inc. (ALVR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1.00 | $1.50 | $0.50 | 25.00% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for AlloVir, Inc. comes to $1.00. The forecasts range from a low of $0.50 to a high of $1.50. The average price target represents an increase of 25% from the last closing price of $0.80.
Analyst Price Targets (4 )
Broker Rating
AlloVir, Inc. currently has an average brokerage recommendation (ABR) of 3.74 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 3.74 a month ago based on five recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 2 | 2 | 2 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.74 | 3.74 | 3.74 | 3.14 | 3.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
12/22/2023 | SVB Securities | Mani Foroohar | Strong Buy | Hold |
12/22/2023 | Piper Sandler | Christopher Raymond | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.74 |
ABR (Last week) | 3.74 |
# of Recs in ABR | 5 |
Average Target Price | $1.00 |
LT Growth Rate | 49.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -0.16 |